Novel tricyclic inhibitors of 1κB kinase

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1994-2005

  Kempson, James ^a,b   Spergel, Steven H ^a,b   Guo, Junqing ^a,b   Quesnelle, Claude ^a,b   Gill, Patrice ^a,b   Belanger, Dominique ^a,b   Dyckman, Alaric J ^a,b   Li, Tianle ^a,b   Watterson, Scott H ^a,b   Langevine, Charles M ^a,b   Das, Jagabandhu ^a,b   Moquin, Robert V ^a,b   Furch, Joseph A ^a,b   Marinier, Anne ^a,b   Dodier, Marco ^a,b   Martel, Alain ^a,b   Nirschl, David ^a,c   Van Kirk, Katy ^a,c   Burke, James R ^a,b   Pattoli, Mark A ^a,b   Gillooly, Kathleen ^a,b   McIntyre, Kim W ^a,b   Laishun, Chen ^a,b   Zheng, Yang ^a,b   Marathe, Punit H ^a,b   Wang Iverson, David ^a,b   Dodd, John H ^a,b   McKinnon, Murray ^a,c   Barrish, Joel C ^a,b   Pitts, William J ^a,b   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b Department of Discovery Chemistry ^*

^c Synthesis and Analysis Technology Team

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIMETHYL 7 METHYLAMINO 2 PHENYL 4H IMIDAZ[4,5 D]IMIDAZO[5,4 B]PYRIDINE; 2 (4 FLUOROPHENYL) 8 METHYL N [2 (1 PIPERIDINYL)ETHYL] 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 5 AMINE; 2 METHANESULFONYL 4 METHYL 7 METHYLAMINO 2 (METHYLTHIO) 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 (AZEPAN 1 YL) 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 (METHYLTHIO) 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 [1,2,3,6 TETRAHYDROPYRIDINE] 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 BENZYLAMINO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 CYCLOPENTYLAMIDO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 DIETHYLAMIDO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 ETHYLAMIDO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 HYDROXYETHYLAMINO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 METHYLAMIDO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 METHYLAMINO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 PHENYL 4H IMIDAZO[4,5 D]OXAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 PHENYL 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 PIPERIDINE 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 4 METHYL 7 METHYLAMINO 2 THIENYLAMIDO 4H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; 8 METHYL 2 (4 FLUOROPHENYL) 8 METHYL 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; I KAPPA B KINASE INHIBITOR; N [2 [[2 (4 FLUOROPHENYL) 8 METHYL 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 5 YL]AMINO]ETHYL]ACETAMIDE; N [2 [[2 (4 FLUOROPHENYL) 8 METHYL 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 5 YL]AMINO]ETHYL]ETHANOL; N [[2 FLUORO 5 (8 METHYL 5 METHYLAMINO 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 2 YL)PHENYL]METHYL]ACETAMIDE; N [[2 FLUORO 5 (8 METHYL 5 METHYLAMINO 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 2 YL)PHENYL]METHYL]METHANESULFONAMIDE; N [[3 [8 METHYL 5 (METHYLAMINO) 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 2 YL]PHENYL]METHYL]ACETAMIDE; N [[3 [8 METHYL 5 (METHYLAMINO) 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 2 YL]PHENYL]METHYL]ISOXAZOLE 5 AMIDE; N [[3 [8 METHYL 5 (METHYLAMINO) 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE 2 YL]PHENYL]METHYL]METHANESULFONAMIDE; N ETHYL 2 (4 FLUOROPHENYL) 8 METHYL 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; N METHYL 2 (4 FLUOROPHENYL) 8 METHYL 8H IMIDAZO[4,5 D]THIAZOLO[5,4 B]PYRIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORMAL HUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; FEMALE; GLUTATHIONE TRANSFERASE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; IMIDAZOLES; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; OXAZOLES; RATS; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64549109718     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8015816     Document Type: Article

References (23)

1. (a) Viemann, D. Transcriptional profiling of IKK2/ NF-κB and p38 MAP kinase dependent gene expression in TNF-R stimulated primary human endothelial cells. Blood 2004, 103, 3365-3373.
2. (b) Neurath, M. F. Role of NF-κB in immune and inflammatory responses in the gut. Gut 1998, 43, 856-860.
3. (c) Cho, M. L. STAT3 and NF-κB signal pathway is required for IL-23 mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 2006, 176, 5652-5661.
4. (d) Zhang, Z. Interleukin-1β and tumor necrosis factor-a upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int. J. Mol. Med. 2005, 15, 79-83.
5. (e) He, K. L.; Ting, A. T. Essential role for IKKg/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur. J. Immunol. 2003, 33, 1917-1924.
6. (f) Snapper, C. M. B cells from p50/NF-κB knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J. Immunol. 1996, 156, 183-191.
7. (g) Ruocco, M. G. IκB kinase (IKK)b, but not IKKa, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 2005, 201, 1677-1687.
8. (h) Pattoli, M. A. Collagen and aggrecan degradation is blocked in interleukin-1-treated cartlidge explants by an inhibitor of IκB kinase through suppression of metalloproteinase expression. J. Pharmacol. Exp. Ther. 2005, 315, 382-388.
9. Whiteside, S. T.; Israel, A. IκB proteins: structure function and regulation. Semin. Cancer Biol. 1997, 8, 75-82.
10. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. Cell 2002, 109, S81-S96.
11. Strnad, J.; Burke, J. R. IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. Trends Pharmacol. Sci. 2007, 28, 142-148.
12. Saklatvala, J. Glucocorticoids: do we know how they work? Arthritis Res. 2002, 4, 146-150.
13. (a) Podolin, P. L. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther. 2005, 312, 373-381.
14. (b) Burke, J. R. BMS-345541 is a highly selective inhibitor of IκB kinase that binds to an allosteric site of the enzyme and blocks NF-κB dependent transcription in mice. J. Biol. Chem. 2003, 278, 1450-1456.
15. (c) Ziegelbauer, K. A selective novel lowmolecular- weight inhibitor of IκB kinase- (IKK-) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br. J. Pharmacol. 2005, 145, 178-192.
16. (d) Wen, D. A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synovicocytes, chondrocytes, and mast cells. J. Pharmacol. Exp. Ther. 2006, 317, 989-1001.
17. (e) Belema, M.; Bunker, A.; Nguyen, V. N.; Beaulieu, F.; Ouellet, C.; Qiu, Y.; Zhang, Y.; Martel, A.; Burke, J. R.; McIntyre, K. W.; Pattoli, M. A.; Daloisio, C.; Gillooly, K. M.; Clarke, W. J.; Brassil, P. J.; Zusi, F. C.; Vyas, D. M. Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3, 2-e)pyrazines as IKK-βl inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 4284-4289.
18. (f) Qiu, Y.; Belema, M.; Yang, X.; Zusi, F. C.; Pitts, W. J. Preparation of Pyrazolopurine-Based Tricyclic Compounds for the Treatment of Inflammatory and Immune Diseases. PCT Int. Appl. WO 2004075846, 2004.
19. (g) Beaulieu, F.; Ouellet, C.; Ruediger, E. H.; Belema, M.; Qiu, Y.; Yang, X.; Banville, J.; Burke, J. R.; Gregor, K. R.; MacMaster, J. F.; Martel, A.; McIntyre, K. W.; Pattoli, M. A.; Zusi, F. C.; Vyas, D. Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1233-1237.
20. Lam, W. W.; Martin, G. E.; Lynch, V. M.; Simonsen, S. H.; Lindsay, C. M.; Smith, K. Chemistry of the phenoxathiins and isosterically related heterocycles. The synthesis of 2-azathianthrene and selected analogs. J. Heterocycl. Chem. 1986, 23, 785-791.
21. Koenigs, E.; Mields, M.; Gurlt, H. Nitrierungsprodukte des γ-aminopyridins. Chem. Ber. 1924, 57, 1179-1187.
22. Manitpisitkul, P.; White, R. E. Whatever happened to cassette-dosing pharmacokinetics? Drug DiscoVery Today 2004, 15, 652-658.
23. The Alamar blue assay was conducted according to the protocol described in Zhi-Jun et al. (J. Immunol. Methods 1997, 210, 25) by using reagents obtained from Biosource International.